---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216716"
form_type: "8-K"
ticker: "AKTS"
cik: "0002035832"
company_name: "Aktis Oncology, Inc."
filed_at: "2026-05-11T20:04:15+00:00"
generated_at: "2026-05-11T22:54:19.626757+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing

## Summary
- Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.
- Cash, equivalents & marketable securities $538.5M (up from $226.8M Dec 2025); runway into 2029.
- Initiated Phase 1b trial of AKY-2519 in mCRPC; second basket trial in H2 2026 for solid tumors.
- AKY-1189 Phase 1b enrolling in multiple Nectin-4 tumors; preliminary data expected Q1 2027; FDA Fast Track for urothelial cancer.
- Collaboration revenue $3.2M from Eli Lilly; appointed Glenn Gormley, MD, PhD to board.

## SEC filing metadata
- accession: 0001193125-26-216716
- form_type: 8-K
- ticker: AKTS
- cik: 0002035832
- company_name: Aktis Oncology, Inc.
- filed_at: 2026-05-11T20:04:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/0001193125-26-216716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/ck0002035832-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216716
- JSON: https://secwatch.observer/filing/0001193125-26-216716.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.